Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| CD19 Loss in ~30% of CAR-T relapses | >95% | Surface expression | Wikipedia |
| CD20 | >95% | Surface expression | Wikipedia |
| CD79b | 95% | surface expression | doi.org |
| CD47 | >90% | Surface expression | Wikipedia |
| ROR1 | 30-50% | IHC, any expression | Wikipedia |
| BCL-2 ~90% in follicular lymphoma t(14;18) | 30-40% | BCL2 translocation/overexpression | Wikipedia |
| EZH2 Tazemetostat withdrawn March 2026 | 20-25% | EZH2 Y641 mutation in follicular/GCB lymphoma | Wikipedia |
| CD30 Hu 2013; CD30-positive DLBCL had better outcome and a distinct gene-expression signature | 14% | IHC, CD30 in 903 de novo DLBCL | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
9 cell lines, 1 mouse models and 2 repositories are listed for this cancer. See them →